Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease

Table 3 Human leukocyte antigen-DRB1* and human leukocyte antigen-DQB1* alleles in donors and recipients, association with recurrent primary sclerosing cholangitis n (%)

	Donor	rPSC	P value	Recipient	rPSC	P value
HLA-DRB1*
1	5	2 (40.0)	1.000	9	3 (33.3)	0.711
3	7	2 (28.6)	0.427	23	11 (47.8)	0.767
4	9	4 (44.4)	1.000	6	0 (0)	0.029
5	1	1 (100)	0.450
6	2	2 (100)	0.196
7	15	10 (66.7)	0.050	2	0 (0)	0.498
8	2	1 (50.0)	1.000
9	1	0 (0)	1.000	1	1 (100)	0.435
10				1	1 (100)	0.435
11	10	4 (40.0)	1.000	5	1 (20.0)	0.369
12	2	2 (100)	0.196	1	1 (100)	0.435
13	8	2 (25.0)	0.258	10	5 (50.0)	0.726
14	4	0 (0)	0.114	1	1 (100)	0.435
15	8	3 (37.5)	0.709	15	5 (33.3)	0.365
16	1	1 (100)	0.450	3	2 (66.7)	0.572
HLA-DQB1*
2	17	9 (53.0)	0.740	25	10 (40.0)	1.000
3	20	8 (40.0)	0.740	11	1 (9.1)	0.030
7	15	6 (40.0)	0.500	7	0 (0)	0.031
8	7	5 (71.4)	0.229	4	0 (0)	0.140
9	2	1 (50.0)	1.000	1	1 (100)	0.395
4	2	1 (50.0)	1.000
5	9	4 (44.4)	1.000	10	5 (50.0)	0.481
6	13	4 (30.8)	0.164	21	9 (42.9)	0.760

rPSC: Recurrent primary sclerosing cholangitis.